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The peri-infarct cerebral cortex exhibits sustained hypo-excitability poststroke that results from tonic inhibition 
via extrasynaptic γ-aminobutyric acid (GABA)A receptors.1,2 
Whereas tonic inhibition may protect ischemic tissue from 
excitotoxic acute injury, it impairs neuronal remodeling and 
plasticity during subsequent stroke recovery. In mice exposed 
to photothrombotic stroke and rats exposed to endothelin 
microinjection, the deactivation of GABAA receptors by the 
inverse GABAA agonist L655708 improved neurological re-
covery.3,4 This effect depended on the presence of the GABAA 
α5 subunit in GABAA receptors. In GABAA α5−/− mice, 
L655708 did not restore neurological deficits.3
S44819 is a potent and competitive GABAA receptor an-
tagonist that preferentially binds to α5 subunit-containing 
GABAA receptors at their GABA-binding site and which has 
no affinity to the benzodiazepine site.5 This GABAA α5 se-
lectivity is governed by amino acid residues within the α5 
subunit F loop—a region associated with GABA binding.5 
In mouse hippocampal CA1 neurons, S44819 enhanced 
hippocampal long-term potentiation and blocked tonic 
currents mediated by extrasynaptic α5 subunit-containing 
GABAA receptors but had no effect on synaptic GABAA re-
ceptor activity.5 In rats and mice, S44819 improved memory 
and reduced anxiety in a variety of cognitive tests, when 
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Background and Purpose—Poststroke, neuronal excitability is tonically reduced in peri-infarct tissue via inhibitory 
influences of extrasynaptic GABAA receptors. We hypothesized that GABAA α5 blockade by the competitive antagonist 
S44819 enhances postischemic neurological recovery, brain remodeling, and neuroplasticity.
Methods—In an explorative study followed by a confirmation study, male C57Bl6/j mice were exposed to transient 
intraluminal middle cerebral artery occlusion. Starting 72 hours poststroke, vehicle or S44819 (3 or 10 mg/kg, BID) was 
delivered orally for 28 days. Neurological recovery, perilesional tissue remodeling, and contralesional pyramidal tract 
plasticity were evaluated for 42 days, that is, 14 days after completion of S44819 delivery.
Results—S44819, delivered at 10 but not 3 mg/kg, persistently improved motor coordination and spatial memory in 
both studies. Striatal atrophy was reduced by 10 mg/kg S44819 at 42 days post-treatment onset, and neuronal long-
term survival in the peri-infarct striatum was increased. Delayed neuroprotection was associated with reduced peri-
infarct astrogliosis, increased peri-infarct brain capillary density, and increased neural precursor cell proliferation and 
differentiation in proximity to the ipsilesional subventricular zone. Contralesional pyramidal tract plasticity, evaluated by 
anterograde tract tracing at the level of the red nucleus, was not influenced by S44819. Concentrations of neurotrophic 
(brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor) and angiogenic (vascular endothelial 
growth factor and basic fibroblast growth factor) growth factors were elevated by 10 mg/kg S44819 in peri-infarct but not 
contralesional brain tissue.
Conclusions—Our data demonstrate that S44819 enhances neurological recovery and peri-infarct brain remodeling in the 
postacute stroke phase.
Visual Overview—An online visual overview is available for this article.   (Stroke. 2018;49:2495-2503. DOI: 10.1161/
STROKEAHA.118.021378.)
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administered orally at doses between 0.3 and 10 mg/kg body 
weight.6
Considering its pharmacological profile, S44819 was evalu-
ated in a randomized double-blinded placebo-controlled phase 
I crossover TMS study (Transcranial Magnetic Stimulation) 
in healthy young humans, in which single 100-mg doses of 
S44819 reduced active motor threshold, that is, the intensity 
needed to produce a motor-evoked potential of 0.5 mV, and the 
amplitude of the N45 potential, that is, a GABAA-ergic com-
ponent of the TMS-evoked electroencephalography response.7 
These observations demonstrated that S44819 reaches human 
cortex to impose an increase in cortical excitability.
Because peri-infarct hypoexcitability impedes stroke re-
covery,3,4 we asked whether the pharmacological inhibition 
of extrasynaptic GABAA receptors by S44819 might promote 
postischemic perilesional brain remodeling and contralesional 
long-distance axonal plasticity, thus enhancing motor coordi-
nation recovery poststroke. Thus, we exposed mice to tran-
sient intraluminal middle cerebral artery occlusion (MCAO), 
administering S44819 orally at 2 doses (3 or 10 mg/kg BID, 
for 28 days) starting at 72 hours poststroke. We evaluated the 
effects of S44819 on neurological recovery for 42 days post-
treatment onset (dpt) using a battery of motor coordination 
and cognitive tests and studied perilesional brain remodel-
ing at 14, 28, and 42 dpt. Following this exploratory study, 
we performed a confirmation study, in which mice exposed 
to transient intraluminal MCAO were identically treated with 
S44819 (3 or 10 mg/kg BID). In these mice, we again exam-
ined S44819 effects on motor coordination and cognitive defi-
cits for 42 days, as well as on poststroke neurogenesis and 
contralesional pyramidal tract plasticity.
Materials and Methods
Legal Issues, Randomization, and Statistical  
Planning
Experiments were performed with local government approval 
(Bezirksregierung Düsseldorf) in accordance to European Union 
(Directive 2010/63/EU) and ARRIVE guidelines (Animal Research 
Reporting of In Vivo Experiments). Experiments were strictly ran-
domized and blinded. Statistical planning of each of the 4 sets of 
studies within the exploratory and confirmatory study assumed an 
α-error of 5% and a β-error (1 - statistical power) of 20%. Details 
are presented in Materials and Methods in the online-only Data 
Supplement. The data that support the findings of this study are avail-
able from the corresponding author on reasonable request.
Stroke Model, Drug Dosing, and Animal Groups
Focal cerebral ischemia was induced in male C57BL6/j mice (11–15 
weeks, 22–25 g; Charles River Laboratories, Cologne, Germany) 
anesthetized with 1.0% to 1.5% isoflurane (30% O2, remainder 
N2O) by 40-minute left-sided intraluminal MCAO, as described be-
fore.8,9 Rectal temperature was maintained between 36.5 and 37.0°C. 
Cerebral blood flow was recorded by measuring laser Doppler flow 
above the middle cerebral artery territory core. From 72 hours until 31 
days poststroke (ie, from 0 until 28 dpt), mice received formulations 
of vehicle (99.5% aqoat, 0.5% magnesium, suspended in 2% hydroxy-
ethyl cellulose) or S44819 (3 or 10 mg/kg; in 30% aqoat milled extru-
date, 69.5% aqoat, 0.5% magnesium, suspended in 2% hydroxyethyl 
cellulose) that were administered twice daily by oral gavage.
For dose selection, pre-experiments were performed in C57BL6/j 
mice, in which 3 mg/kg S44819 administered by oral gavage yielded 
peak plasma, brain, and cerebrospinal fluid concentrations of 
105.89±27.26 ng/ml, 41.66±12.60 ng/g, and 39.13±2.57 mg/ml, respec-
tively, after 2 hours.6 Based on cerebrospinal fluid measurements from 
phase I studies, this dose was considered equivalent to 100 mg doses 
orally in human subjects that have previously been reported to increase 
cortical excitability in the TMS paradigm.7 To allow for dose-response 
assessments, an additional dose of 10 mg/kg S44819 was chosen.
In the first study that was scheduled as an exploratory study, 1 set 
of mice (animal set 1) received detailed assessments of motor coor-
dination and cognitive deficits by rotarod, tightrope, open-field, and 
Barnes maze tests (Figure IA in the online-only Data Supplement).8–10 
These animals were sacrificed at 42 dpt by transcardiac perfusion with 
4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS; n=18 
animals per group).
Another set of mice within the exploratory study (animal set 2) 
was sacrificed at 14, 28, or 42 dpt (each n=6 per group) by transcar-
diac perfusion with 4% paraformaldehyde in 0.1 M PBS (Figure IB 
in the online-only Data Supplement). These animals were used for 
histochemistry.
A third set of mice within the exploratory study (animal set 3) 
was sacrificed at 14, 28, or 42 dpt (each n=6 per group) by transcar-
diac perfusion with normal saline (Figure IC in the online-only Data 
Supplement). Additional animals subjected to 40-minute left-sided 
MCAO or sham surgery (n=6 per group) neither received vehicle nor 
S44819. These animals were transcardially perfused with normal sa-
line at 72 hours poststroke or post-sham surgery and used for ELISA.
Following the exploratory study, a confirmatory study (animal set 
4) was conducted in mice exposed to 40-minute left-sided MCAO, 
which were identically treated with vehicle or S44819 (3 or 10 mg/kg) 
as before (n=18 animals per group; Figure ID in the online-only Data 
Supplement) and in which rotarod, tightrope, open-field, and Barnes 
maze tests were again performed. These animals received daily intra-
peritoneal injections of bromodeoxyuridine (BrdU; 50 mg/kg) on 3 to 
8, 8 to 13, or 13 to 18 dpt (6 animals per group each). These animals 
obtained injections of the anterograde tract-tracer biotinylated dex-
tran amine into the contralesional motor cortex at 42 dpt8,9 and were 
sacrificed by transcardiac perfusion with 4% paraformaldehyde in 0.1 
M PBS at 49 dpt. These animals were used for studying endogenous 
neurogenesis and contralesional pyramidal tract plasticity.
Details are presented in Materials and Methods in the online-only 
Data Supplement. The animal flow is summarized in Table I in the 
online-only Data Supplement.
Behavioral Tests
Motor coordination deficits was analyzed using the Rotarod and tight-
rope tests at baseline (ie, before MCAO), before treatment onset (ie, 
at 3 days after MCAO), and at weekly intervals after treatment onset. 
Spontaneous motor activity and anxiety were examined by open-field 
tests at 7 and 28 dpt and spatial memory assessed by Barnes maze 
tests at 8 to 19 dpt (for details, see Materials and Methods in the 
online-only Data Supplement).
Analysis of Brain Atrophy
Whole brain, striatal, and hippocampal atrophy were volumet-
rically evaluated using cresyl violet-stained 20-µm-thick cor-
onal brain sections that had been collected at millimeter intervals 
throughout the forebrain.8,9
Immunohistochemistry for Neuronal, Astrocytic, 
Microglial, and Endothelial Markers
Neuronal survival, astrocytic reactivity, microglial activation, and 
brain capillary density were analyzed in 20-µm-thick brain sections 
using cresyl violet (ie, Nissl) staining and NeuN (neuronal nuclear 
antigen), GFAP (glial fibrillary acidic protein), Iba1 (ionized cal-
cium-binding adaptor protein), or CD31 (cluster of differentiation 31) 
immunohistochemistry, as described in Materials and Methods in the 
online-only Data Supplement. Immunohistochemistries were coun-
terstained with the nuclear marker 4′,6-diamidino-2-phenylindole 
(DAPI). Cresyl violet+ neurons, which could be identified based on 
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the appearance of Nissl staining in surviving neurons, NeuN+ neu-
rons, GFAP+ astrocytes, and Iba1+ microglia were blindly quantified 
under a motorized Zeiss AxioObserver.Z1 inverted epifluorescence 
microscope equipped with Apotome optical sectioning by measuring 
cell numbers in 6 defined regions of interest of the striatum ipsilateral 
to the stroke (size, 500×500 µm; regions of interest centered 1.5 and 
2.5 mm lateral to midline/2.5, 3.25, and 4.0 mm below brain sur-
face), as specified in Figure IE in the online-only Data Supplement.8,9 
For cresyl violet and NeuN stainings, neuronal densities determined 
were multiplied with striatal areas of each section, thus correcting 
for consequences of brain atrophy. CD31 stainings were evaluated by 
counting microvessel numbers in the same regions of interest. Optical 
sectioning was used for correction of cell/capillary overcounts. Mean 
values were calculated for all regions of interest.
Immunohistochemistry for Endogenous  
Neurogenesis
Endogenous neural precursor cell (NPC) proliferation and differ-
entiation were examined in 20-µm-thick brain sections obtained 
from the bregma level by colabeling with anti-BrdU and anti-DCX 
(doublecortin) or anti-BrdU and anti-NeuN antibodies. Nuclei were 
counterstained with DAPI. Sections were evaluated using a Carl Zeiss 
LSM 710 confocal microscope by nonbiased colabeling analysis of 
maximum-intensity projections obtained from 666×666×10 µm stacks 
in the ipsilesional subventricular zone, peri-infarct striatum, and peri-
infarct cortex using customized automated algorithms (for details, see 
Materials and Methods in the online-only Data Supplement).
Immunohistochemistry for Biotinylated Dextran  
Amine
Corticorubral plasticity was evaluated in 2 consecutive 40-µm-thick 
brain sections obtained from the level of the parvocellular red nu-
cleus that were incubated with avidin-biotin-peroxidase complex and 
revealed by 3,3′-diaminobenzidine (DAB). Using an Olympus BX42 
microscope, the number of tracer-stained fibers crossing a 500-µm-
long intersection line on the brain midline were quantified.8,9,11 These 
fibers originate from the contralesional pyramidal tract and innervate 
the ipsilesional red nucleus. The number of fibers counted was di-
vided by the total number of labeled fibers that was evaluated in the 
pyramidal tract and multiplied with 100, resulting in percent values of 
fibers crossing the midline (Materials and Methods in the online-only 
Data Supplement).
ELISA
In homogenates of peri-infarct striatum and cortex and homologous 
contralesional striatum and cortex, levels of BDNF (brain-derived 
neurotrophic factor), GDNF (glial cell line-derived neurotrophic 
factor), VEGF (vascular endothelial growth factor), and basic FGF 
(fibroblast growth factor) were determined using commercial kits 
(Materials and Methods in the online-only Data Supplement).
Statistical Analysis
Data were analyzed by 2-way or 2-way repeated measures 
ANOVA, followed by Bonferroni-corrected 2-tailed t tests as 
post hoc tests. Data were presented as mean±SD (longitudinal 
comparisons within the same animals) or in box blots as median/
mean±interquartile range with minimum and maximum data (all 
other comparisons between animals or tissue samples). P values 
<0.05 were considered significant.
Results
Postacute Delivery of S44819 Improves Poststroke 
Motor Coordination Recovery and Spatial Memory
Body weight and laser Doppler flow above the core of the 
middle cerebral artery territory did not differ between animals 
treated with vehicle or S44819 (3 or 10 mg/kg), neither in the 
exploratory study (Figure IIA and IIB in the online-only Data 
Supplement) nor in the confirmation study (Figure IIIA and 
IIIB in the online-only Data Supplement) nor when both stud-
ies were evaluated in a combined analysis (Figure 1A and 1B). 
In all groups, laser Doppler flow decreased to ≈15% of base-
line during MCAO, followed by a rapid blood flow recovery 
after reperfusion. Motor coordination performance, assessed 
by Rotarod and tightrope tests, was markedly impaired 3 days 
poststroke, before the start of treatment. From 14 dpt, motor 
coordination deficits were significantly improved by S44819 
delivered at a dose of 10 mg/kg but not at 3 mg/kg, both when 
both studies were evaluated separately (Figures IIC, IID, IIIC, 
and IIID in the online-only Data Supplement) and in a com-
bined analysis (F [2/105], 19.434; P<0.001 for Rotarod/F 
[2/105], 29.989; P<0.001 for tightrope test; Figure 1C and 
1D). The improvement of motor coordination skills was main-
tained until 42 dpt, that is, 14 days after the termination of 
S44819 delivery.
In line with the motor coordination improvement, spon-
taneous motor activity, evaluated as distance covered in the 
open-field test, was not influenced by S44819 (Figure 2A). 
Anxiety, examined by the time spent in the center of the 
open-field arena, was moderately but significantly reduced 
by 10 mg/kg S44819 at 28 dpt (F [2/69], 5.717; P=0.005; 
Figure 2B). The time spent in the border and corner zone was 
unchanged (Figure 2C and 2D).
In the Barnes maze test, which was conducted between 8 
and 19 dpt, spatial memory, evaluated as the number of errors 
(F [2/105], 3.488; P=0.035) and latency (F [2/105], 4.279; 
P=0.016) until finding the target hole, was reduced by 10 mg/
kg but not 3 mg/kg S44819 in the combined analysis (Figure 
IVA and IVB in the online-only Data Supplement). In post hoc 
tests, target hole latency was significantly reduced by 10 mg/
kg S44819 at 19 dpt.
Postacute S44819 Administration Prevents Secondary 
Striatal Atrophy and Promotes Delayed Neuronal  
Survival
Cresyl violet stainings revealed progressive shrinkage of 
the striatum and parietal cortex from 14 to 42 dpt. Notably, 
the volume of the striatum, which represents the core of the 
middle cerebral artery territory,12 was significantly increased 
by 10 mg/kg but not 3 mg/kg S44819 at 42 dpt (Figure 3A), 
whereas whole brain volume (Figure VB in the online-only 
Data Supplement) and hippocampal volume (Figure VC in the 
online-only Data Supplement) were not significantly altered. 
Neuronal survival in the striatum was significantly increased 
by 10 but not 3 mg/kg S44819 at 14 dpt and, more pro-
nounced, 42 dpt, as shown by NeuN (Figure 3B) and cresyl vi-
olet (ie, Nissl; Figure VA in the online-only Data Supplement) 
histochemistry.
S44819 Delivery Reduces Peri-Infarct Astrogliosis 
and Increases Brain Capillary Density
Peri-infarct astrogliosis, evaluated by GFAP immunohisto-
chemistry in brain sections, was significantly decreased by 10 
but not 3 mg/kg S44819 at 14, 28, and 42 dpt (Figure 3C). 
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Microglial activation, defined by Iba1 immunoreactivity, was 
not influenced by S44819 at both doses (Figure VD in the 
online-only Data Supplement), whereas brain capillary den-
sity, examined by CD31 immunohistochemistry, was signifi-
cantly increased by 10 mg/kg at 42 dpt (Figure 3D).
S44819 Enhances NPC Proliferation and Neuronal 
Differentiation in the Ipsilesional Subventricular Zone
To test whether the enhanced peri-infarct brain remodeling was 
associated with increased neurogenesis, we next assessed NPC 
proliferation and differentiation by BrdU incorporation analysis 
Figure 1. Delayed delivery of S44819 at 10 mg/kg but not 3 mg/kg promotes postischemic recovery of motor coordination deficits. Combined analysis of 
the exploratory study (animal set 1) and confirmatory study (animal set 4). A, Body weight, (B) laser Doppler flow (LDF) recordings above the middle cerebral 
artery territory core, and (C and D) coordination skills evaluated by Rotarod and tightrope tests in mice exposed to transient middle cerebral artery occlusion 
(MCAO). Vehicle or S44819 (3 or 10 mg/kg BID) was administered for 28 d starting 72 h after reperfusion. Body weight (A) and LDF recordings (B) do not dif-
fer between groups. Results are means±SD values (n=36 animals per group). *P<0.05, ***P<0.001 compared with vehicle.
Figure 2. Delayed S44819 delivery at 10 mg/kg but not 3 mg/kg enhances postischemic exploration behavior. Combined analysis of the exploratory study 
(animal set 1) and confirmatory study (animal set 4). A, Distance covered, (B) time in center, (C) time in border zone, and (D) time in corner zone in open-field 
tests of mice exposed to transient middle cerebral artery occlusion (MCAO). Vehicle or S44819 (3 or 10 mg/kg BID) was administered for 28 d starting 72 h 
after reperfusion. Results are medians (lines inside boxes)/means (crosses inside boxes)±interquartile range (boxes) and minimum/maximum data (elongation 
lines; n=36 animals per group). *P<0.05 compared with vehicle.
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in animals, in which BrdU had been administered at 3 defined 
time intervals, that is, from 3 to 8, 8 to 13, or 13 to 18 dpt. 
Compared with vehicle-treated animals, enhanced cell prolifera-
tion was observed adjacent to the ipsilesional subventricular zone 
(Figure 4A) but not in the perilesional striatum (Figure VIA in 
the online-only Data Supplement) or the peri-infarct cortex (not 
shown) of animals treated with 3 or 10 mg/kg S44819, in which 
BrdU had been delivered at 13 to 18 dpt. Similarly, NPC differ-
entiation, examined by BrdU colabeling with the immature neu-
ronal marker DCX, but not NPC differentiation, assessed by BrdU 
colabeling with the mature neuronal marker NeuN, was signifi-
cantly increased adjacent to the ipsilesional subventricular zone 
Figure 3. S44819 prevents delayed neurodegeneration and promotes peri-infarct brain remodeling. A, Striatal volume, outlined on cresyl violet-stained brain 
sections; (B) neuronal density, evaluated by NeuN (neuronal nuclear antigen) immunohistochemistry; (C) astrogliosis, examined by GFAP (glial fibrillary acidic 
protein) immunohistochemistry; and (D) capillary density, analyzed by CD31 (cluster of differentiation 31) immunohistochemistry, in mice exposed to transient 
middle cerebral artery occlusion (MCAO) that were treated with vehicle or S44819 (3 or 10 mg/kg BID) starting 72 h after reperfusion. Photomicrographs at 42 
d post-treatment onset (dpt) are also shown. Cell and capillary densities were assessed in 6 regions of interest within the striatum, as described in Materials 
and Methods in the online-only Data Supplement and depicted in Figure IE in the online-only Data Supplement. Representative microphotographs taken at 42 
dpt are shown. Results are medians (lines inside boxes)/means (crosses inside boxes)±interquartile range (boxes) and minimum/maximum data (elongation 
lines; n=6 animals per group). Bars=1000 µm (A)/50 µm (B–D). *P<0.05, **P<0.01, ***P<0.001 compared with vehicle.
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(Figure 4B and 4C) but not in the peri-infarct striatum (Figure 
VIB and VIC in the online-only Data Supplement) or the peri-
infarct cortex (not shown) of animals, in which BrdU had been 
delivered at 8 to 13 or 13 to 18 dpt. These observations support 
the existence of a time interval between 8 and 18 dpt (ie, 11–21 
days poststroke), in which precursor cell proliferation and dif-
ferentiation were stimulated adjacent to the ipsilesional subven-
tricular zone. As a matter of fact, this response did not translate 
into enhanced neurogenesis in previously ischemic brain tissue.
S44819 Does Not Influence Contralesional 
Pyramidal Tract Plasticity
To evaluate whether neurological recovery induced by 
S44819 involved contralesional pyramidal tract plasticity, 
we next evaluated the density of midline-crossing pyramidal 
tract fibers originating from the contralesional motor cortex 
in direction to the ipsilesional parvocellular red nucleus after 
vehicle and S44819 delivery (Figure 5A). This corticoru-
bral projection has previously been shown to exhibit robust 
sprouting after intraluminal MCAO in response to therapy 
with different growth factors8,11 and NPCs.13 The density of 
midline-crossing fibers that had anterogradely been labeled 
with biotinylated dextran amine did not differ between ve-
hicle- and S44819-treated (3 or 10 mg/kg) animals (Figure 5B 
and 5C), as did pyramidal tract area at the level of the red nu-
cleus (Figure 5D). These findings argued against significant 
long-distance axonal sprouting that was evoked in the contral-
esional pyramidal tract system in response to S44819.
S44819 Increases Growth Factor Levels in the 
Peri-Infarct but Not Contralesional Brain Tissue
To further characterize restorative responses, we finally evalu-
ated concentrations of growth factors in both brain hemispheres 
before treatment onset and at 14, 28, and 42 dpt by ELISA. 
Interestingly, concentrations of neurotrophic growth factors 
(BDNF and GDNF) and preferentially angiogenic growth fac-
tors (VEGF and FGF) were significantly elevated in peri-infarct 
brain tissue by 10, but not 3 mg/kg S44819 at 28 dpt (GDNF 
and FGF) and 42 dpt (all 4 growth factors; Figure 6A through 
6D). Growth factor concentrations in the corresponding con-
tralesional tissue were not influenced by S44819 (Figure VIIA 
through VIID in the online-only Data Supplement).
Discussion
We herein show that the preferential GABAA α5 antagonist 
S44819 induces sustained postischemic neurological recovery, 
when delivered in the postacute stroke phase starting at 3 days 
after transient MCAO. To substantiate this finding, we performed 
2 behavioral studies, an exploratory study that was endorsed by a 
subsequent confirmation study, both studies having an adequate 
statistical power and size to detect recovery-promoting effects. 
Neurological recovery, which persisted after the completion of 
S44819 treatment, was associated with peri-infarct brain remod-
eling, that is, prevention of secondary striatal atrophy, promotion 
of peri-infarct neuronal survival, inhibition of peri-infarct astro-
gliosis, promotion of peri-infarct brain capillary density, and 
promotion of subventricular zone neurogenesis. Contralesional 
Figure 4. S44819 increases neural precursor cell (NPC) proliferation and differentiation in proximity to the subventricular zone. NPC (A) proliferation and (B and 
C) differentiation adjacent to the ipsilesional subventricular zone, as revealed by bromodeoxyuridine (BrdU) incorporation and colabeling of BrdU incorporating 
cells (in red in A–C) with the immature neuronal marker DCX (doublecortin; in green in B) and the mature neuronal marker NeuN (neuronal nuclear antigen; in 
green in C) in mice exposed to transient middle cerebral artery occlusion (MCAO) that were treated with vehicle or S44819 (3 or 10 mg/kg BID) starting 72 h 
after reperfusion. BrdU was intraperitoneally administered at 3 to 8, 8 to 13, or 13 to 18 d post-treatment onset (dpt), respectively. Photomicrographs for an-
imals receiving BrdU at 13 to 18 dpt are also shown. Sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI; in blue). Results are medians 
(lines inside boxes)/means (crosses inside boxes)±interquartile range (boxes) and minimum/maximum data (elongation lines; n=6 animals per group). Bars=100 
µm. *P<0.05, **P<0.01 compared with vehicle.
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pyramidal tract plasticity, evaluated by anterograde tract tracing 
at the level of the red nucleus, was not influenced by S44819. 
Concentrations of neurotrophic growth factors (BDNF and 
GDNF) and angiogenic growth factors (VEGF and FGF) were 
increased in peri-infarct but not contralesional brain tissue. Our 
data reveal a profound restorative response in the peri-infarct 
brain tissue that prevents neurodegeneration and enables neu-
rological recovery (visual overview).
In models of permanent MCAO, that is, photothrombotic 
stroke in mice and cortical endothelin microinjection in rats, 
improvement of neurological deficits has repeatedly and con-
sistently been reported after delayed subcutaneous or intra-
peritoneal delivery of the negative allosteric GABAA modulator 
L6557083,4, which similarly to S44819 reverses tonic GABA-
ergic inhibition. The recovery-promoting effect of L655708 was 
absent in ischemic GABAA α5−/− mice, indicating that the de-
activation of the GABAA α5 subunit was critical for neurolog-
ical recovery.3 S44819 differs from L655708 in that it is the first 
competitive antagonist of GABAA receptors that selectively 
interacts at the GABA-binding site of GABAA α5 receptors and 
does not bind to the benzodiazepine site.5 Our observations for 
S44819 exceed results from L655708 studies by showing that 
S44819 reduces secondary brain atrophy, increases long-term 
peri-infarct neuronal survival, reduces peri-infarct astrogliosis, 
increases peri-infarct brain capillary density, and augments NPC 
proliferation and differentiation in the subventricular zone.
S44819 exhibits high affinity to GABAA α5 receptors 
(Ki=6.6×10−8 M)5 and less potent affinity to GABAA α1, α3, and 
α4 receptors (Ki=7.1×10−7, 6.6×10−6, and 6.9×10−7 M, respec-
tively), while not interacting with GABAA α2 receptors. In vitro, 
under conditions mimicking extrasynaptic GABA exposure, 
S44819 acts as competitive antagonist of recombinant GABAA 
α5 and α4 but not GABAA α1 and α3 receptors in human em-
bryonic kidney (HEK) 293 cells (unpublished data). Ex vivo, 
S44819 (10−5 M) inhibits α5-mediated but not α4-mediated 
tonic currents in mouse hippocampal and thalamic slices.5 These 
data suggest that S44819 is a highly selective GABAA α5 antag-
onist. Although effects on GABAA α4 receptors could not en-
tirely be excluded, effects on other GABAA receptor subtypes 
could be excluded. S44819 has previously been administered al-
ready to rats twice daily for 28 days at doses 10× above those we 
used. There was no drug accumulation: S44819 concentrations 
after morning dosing were very similar on days 1 and 28 (un-
published). S44819 reaches its peak plasma concentrations 1 to 
2 hours after oral administration in rats and mice. The compound 
is rapidly cleared in both species (half-life, ≈5 hours).
Figure 5. S44819 does not increase contralesional pyramidal tract plasticity at the level of the red nucleus. A, Midline-crossing fibers originating from the 
contralesional motor cortex in direction to the ipsilesional parvocellular red nucleus were evaluated by injection of the anterograde tract-tracer biotinylated 
dextran amine (BDA) into the contralesional motor cortex. B, Percentage of BDA-labeled midline-crossing fibers at the level of the red nucleus originating 
from the contralesional motor cortex after intraperitoneal delivery of vehicle or S44819 (3 or 10 mg/kg BID). No significant differences were noticed between 
groups. Representative microphotographs are depicted in (C) (midline shown in blue, midline-crossing fibers labeled as red dots). D, Total area of the contral-
esional pyramidal tract at the level of the red nucleus, which does not change in response to S44819 delivery, indicating the absence of contralesional cor-
ticospinal tract degeneration. Data are medians (lines inside boxes)/means (crosses inside boxes)±interquartile range (boxes) and minimum/maximum data 
(elongation lines). Bars=30 µm (C).
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For evaluating effects of S44819, we used a protocol very 
similar to protocols that we previously used for evaluating 
effects of growth factors,8,11 NPCs,12,13 and other pharmaco-
logical compounds9 in the postacute stroke phase. S44819 
delivery was initiated at 3 days after transient intraluminal 
MCAO, and motor coordination and cognition were studied 
for 6 weeks, that is, 2 weeks after the completion of treat-
ment, using comprehensive test batteries. Structural brain 
remodeling was examined using histochemical and BrdU in-
corporation studies. Interestingly, the time window at which 
neurological recovery occurred after S44819 administration 
was faster than after growth factor or NPC delivery, sug-
gesting both a rapid symptomatic and a delayed restorative 
effect. After growth factor8,11 or NPC12,13 delivery, neurolog-
ical improvements gradually evolved for 4 to 6 weeks post-
treatment onset.
S44819 induced a marked inhibition of astrogliosis, 
which was evident already at 2 weeks post-treatment onset 
and persisted after the termination of S44819 treatment. Brain 
astrocytes do express GABAA receptors,14 and they may fur-
thermore attenuate tonic inhibition under pathophysiological 
conditions via GABA uptake.15 These observations raise the 
possibility that the effects of S44819 on neurological recovery 
and secondary neurodegeneration might at least partly be 
mediated by astrocytes, perhaps by increasing their release 
of growth factors. Notably, S44819’s effects on astrogliosis, 
brain atrophy, and neuronal survival were noted only at a dose 
of 10 but not 3 mg/kg S44819, as were effects on neurolog-
ical recovery. Hence, slightly higher S44819 doses (10 mg/kg) 
were needed than those predicted in pre-experiments (3 mg/
kg), in which brain and plasma S44819 concentrations had 
been determined (see Materials and Methods).
Although the proliferation and differentiation of NPCs were 
elevated adjacent to the subventricular zone by S44819 at 8 to 
18 dpt, as revealed by BrdU incorporation analysis and cola-
beling with the immature neuronal marker DCX, we did not 
find evidence for NPC proliferation or differentiation in pre-
viously ischemic striatum and cortex. GABA is a well-known 
modulator of subventricular zone NPCs that controls neuronal 
differentiation both via activity-dependent synaptic and extra-
synaptic GABAA receptors.16 In an unbiased high-throughput 
genome-wide study, GABA was shown to control neurogenesis 
in an activity-dependent way via the transcriptional regulator 
NFAT (nuclear factor of activated T cells)-c4, which via bind-
ing to specific promoter-responsive elements regulated GABAA 
α2 and GABAA α4 subunit expression.17 In a mouse model of 
Down syndrome, in which spatial learning and memory are im-
paired because of excessive tonic inhibition, reversal of tonic 
inhibition by the GABAA α5-negative allosteric modulator 
RO4938581 restored deficits in spatial learning and memory 
and adult neurogenesis.18 The role of GABAA α5 receptors in 
the stroke brain differs from GABAA α1 receptors, which, when 
activated by zolpidem starting 3 days poststroke, enhance neu-
rological recovery by activating phasic GABAA currents.19
In this study, the midline sprouting of biotinylated dex-
tran amine–labeled contralesional pyramidal tract fibers was 
not increased by S44819, indicating that long-distance axonal 
plasticity in lesion-remote brain areas was unaffected. With this 
respect, S44819 differs from growth factors,8,11 NPCs,12,13 and 
the N-methyl-D-aspartate (NMDA) antagonist memantine,9 
Figure 6. S44819 elevates neurotrophic and angiogenic growth factors in the peri-infarct brain tissue. Concentrations of (A) BDNF (brain-derived neurotrophic 
factor), (B) GDNF (glial cell line-derived neurotrophic factor), (C) FGF (fibroblast growth factor), and (D) VEGF (vascular endothelial growth factor) in peri-infarct 
striatum and cortex evaluated by ELISA in mice exposed to transient middle cerebral artery occlusion (MCAO) or sham surgery that were treated with ve-
hicle or S44819 (3 or 10 mg/kg BID) starting 72 h after reperfusion. Results are medians (lines inside boxes)/means (crosses inside boxes)±interquartile range 
(boxes) and minimum/maximum data (elongation lines; n=6 animals per group). *P<0.05 compared with ischemic vehicle.
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for which our group has previously reported enhanced con-
tralesional pyramidal tract plasticity after transient intralumi-
nal MCAO in mice. That S44819 did not influence neuronal 
plasticity at distance to the stroke might be attributable to the 
fact that tonic inhibition is a local phenomenon that is con-
fined to peri-infarct brain tissue.1,2 In line with this finding, 
brain tissue levels of the growth factors BDNF, GDNF, VEGF, 
and FGF were elevated by S44819 in the peri-infarct brain 
tissue. We did not evaluate receptors or downstream signals 
of growth factors that establish causal links to neuroplasticity. 
The GABAA α5 subunit has previously been involved in neu-
ronal long-term potentiation and synaptic plasticity.20
We were surprised to see that GABAA α5 deactivation 
increased peri-infarct brain capillary density. This finding may 
result from elevations of angiogenic growth factors (VEGF and 
FGF) that promoted microvascular remodeling and growth.
The clear strength of this study is the use of a study pro-
tocol that used well-defined batteries of functional neurolog-
ical tests and sets of histochemical analyses, which our group 
previously used in the evaluation of other experimental thera-
pies. Each of the 2 behavioral studies was adequately powered 
to detect improvements of motor coordination deficits with 
80% statistical power (1 - β-error) and 5% α-error. Hence, this 
study fulfilled the principles of a hypothesis-building study that 
was confirmed by a second independent data set. This study 
complied with state-of-the-art principles of animal randomiza-
tion and data blinding. Hence, our study raises hopes that the 
GABAA α5 antagonist S44819, which is currently evaluated in 
a randomized controlled phase IIb stroke trial in 15 countries 
on 5 continents (RESTORE Brain [Randomized Efficacy and 
Safety Trial With Oral S44819 After Recent Ischemic Cerebral 
Event]), might also be effective in human patients.
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